Clinical Trials · NCT03529123
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 247
- Start date
- Jun 2018
- Locations
- 13 sites, India
- Primary endpoint
- Change in HbA1c